Dainippon To Buy Kyowa’s Chinese Unit For Production Facility
This article was originally published in PharmAsia News
Executive Summary
Japan's Dainippon Sumitomo Pharma plans to buy a Chinese subsidiary of Kyowa Hakko Kirin, also of Japan. The price of the acquisition was not revealed, but is estimated at about $15.7 million. The agreement would give Dainippon control of Kyowa Hakko Pharmaceuticals, which has a production plant capable of making about 100 million doses a year, but yet to be placed into service. The deal is believed to fit Dainippon's operating style because it now exports products from Japan to China. Dainippon expects to have the Kyowa plant in operation in 2010. (Click here for more - a subscription may be required